GUTS
Fractyl Health, Inc. Common Stock
There isn't enough reported data to score GUTS yet.
GUTS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
GUTS's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
GUTS PE Valuation
GUTS has no meaningful PE right now: it lost money over the past year.
GUTS Forward outlook
There aren't enough analyst estimates for GUTS to show an outlook.
GUTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$28.56 | -$11.64 |
| Q2 2025 | -$25.80 | -$9.60 |
| Q1 2025 | -$23.28 | -$3.84 |
| Q4 2024 | -$19.44 | +$0.96 |
| Q3 2024 | -$16.92 | +$1.44 |
| Q2 2024 | -$16.20 | -$0.12 |
| Q1 2024 | -$19.44 | -$6.72 |
| Q4 2023 | -$20.40 | -$6.48 |
GUTS lost $28.56 per share over the past year, a bigger loss than the year before.
GUTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $3K | -57% |
| Q3 2024 | $14K | -61% |
| Q2 2024 | $43K | -40% |
| Q1 2024 | $33K | +560% |
GUTS's revenue has slid since its 2023 peak: $3,000 last quarter, down 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -840333% | -654891 points |
| Q3 2024 | -169957% | -131421 points |
| Q2 2024 | -53453% | -36960 points |
| Q1 2024 | -65279% | +176861 points |
| Q4 2023 | -185443% | N/A |
| Q3 2023 | -38536% | N/A |
| Q2 2023 | -16493% | N/A |
| Q1 2023 | -242140% | N/A |
GUTS's operating margin was −840333% last quarter, down 654890 points from the same quarter a year ago, near the bottom of its range since 2023.
GUTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$21.3M | -$4.1M |
| Q3 2025 | -$22.7M | -$4.5M |
| Q2 2025 | -$21.3M | -$2.3M |
| Q1 2025 | -$25.5M | -$12.8M |
| Q4 2024 | -$17.3M | -$6.5M |
| Q3 2024 | -$18.3M | -$7.1M |
| Q2 2024 | -$19M | -$7.3M |
| Q1 2024 | -$12.8M | -$3.2M |
GUTS has burned cash in almost every quarter: −$91M over the past year, against −$67M the year before.
GUTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +29.3K shares |
| 1 year | +224% | +9.2M shares |
| 3 years | +233% | +9.3M shares |
| 5 years | +234% | +9.3M shares |
GUTS has 13M diluted shares, up 224% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
GUTS Net Leverage
GUTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GUTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.9 | Oversold |
| Stochastic | 1.0 | Oversold |
GUTS's weekly RSI is 25 (oversold) and its Stochastic is 1 (oversold).
GUTS PE vs Healthcare Sector
GUTS has no meaningful PE right now: it lost money over the past year.
GUTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.56 | 68% below |
| 20 week MA | $6.17 | 87% below |
| 50 week MA | $9.75 | 92% below |
| 100 week MA | $13.9 | 94% below |
GUTS is in a downtrend: it's below all four of its weekly moving averages, and 94% below its 100-week average.
GUTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $154.2 | $23.6 | -85% |
| 2025 | $23.6 | $27.2 | +15% |
| 2026 YTD | $27.2 | $0.81 | -97% |
GUTS has finished lower in one of the last two years. It's down 97% so far in 2026.